Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 1/2018

Content (15 Articles)

Original Article

The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer

Mohammad W. Khan, Abdulrahman Saadalla, Ahmed H. Ewida, Khalid Al-Katranji, Ghadier Al-Saoudi, Zachary T. Giaccone, Fotini Gounari, Ming Zhang, David A. Frank, Khashayarsha Khazaie

Original Article

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

Paulina Nowakowska, Annette Romanski, Nicole Miller, Marcus Odendahl, Halvard Bonig, Congcong Zhang, Erhard Seifried, Winfried S. Wels, Torsten Tonn

Original Article

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Stefan Diem, Omar Hasan Ali, Christoph J. Ackermann, David Bomze, Viktor H. Koelzer, Wolfram Jochum, Daniel E. Speiser, Kirsten D. Mertz, Lukas Flatz

Original Article

Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression

Jonathan P. O. Hebb, Adriane R. Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén, Peter Ellmark, Dean W. Felsher

Original Article

Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat model

Kerem Teke, Nil Guzel, Ali Kemal Uslubas, Murat Kasap, Hasan Yilmaz, Gurler Akpinar, Demir Kursat Yildiz, Ozdal Dillioglugil

Original Article

HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients

Jiajun Wang, Li Liu, Yang Qu, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo

Original Article

Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer

Jitka Fucikova, Michal Podrazil, Ladislav Jarolim, Pavla Bilkova, Michal Hensler, Etienne Becht, Zdenka Gasova, Jana Klouckova, Jana Kayserova, Rudolf Horvath, Anna Fialova, Katerina Vavrova, Klara Sochorova, Daniela Rozkova, Radek Spisek, Jirina Bartunkova

Original Article

Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth

Nikolai N. Belyaev, Nurshat Abdolla, Yuliya V. Perfilyeva, Yekaterina O. Ostapchuk, Vladimir K. Krasnoshtanov, Aikyn Kali, Raikhan Tleulieva

Original Article

Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules

Atsunari Kawashima, Takayuki Kanazawa, Kumiko Goto, Mitsunobu Matsumoto, Akiko Morimoto-Okazawa, Kota Iwahori, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Motohide Uemura, Norio Nonomura, Hisashi Wada

Original Article

Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study

Daniel Franzen, Karin Schad, Benedikt Kowalski, Christian F. Clarenbach, Roger Stupp, Reinhard Dummer, Malcolm Kohler

Original Article

Safety of shortened infusion times for combined ipilimumab and nivolumab

Maximilian Gassenmaier, Hans-Peter Lipp, Alexander Scheu, Nikolaus Benjamin Wagner, Lukas Kofler, Alisa Mueller, Dennis Doecker, Thomas Kurt Eigentler, Claus Garbe, Andrea Forschner

Original Article

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

Tímea Balatoni, Anita Mohos, Eszter Papp, Tímea Sebestyén, Gabriella Liszkay, Judit Oláh, Anita Varga, Zsuzsanna Lengyel, Gabriella Emri, István Gaudi, Andrea Ladányi

Meeting Report

2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece

Pinelopi Samara, Athanasios Kotsakis, Ourania Tsitsilonis, Vassilis Georgoulias, Graham Pawelec, Constantin N. Baxevanis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine